Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors

NCT07362888 is registered in ClinicalTrials.gov with Adcendo ApS as lead sponsor.

NCT NCT07362888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07362888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors
Lead sponsor
Adcendo ApS
Phase
Phase 1
Overall status
Recruiting
Start date
March 17, 2026
Completion date
March 14, 2029
Enrollment
180 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors (phase 1)